Biotech Values

[apljack]

JAV: "i would imagine with the ketorolac data showing bleeding with repeat dosing this is not only prudent to have in the NDA for approval, but to get a better label which would be huge commercially. I remember when toradol first came out - i was a resident managing a lot of post-ops and using toradol like crazy and then the black box restriction (i think it was no more than 4-5 doses allowed) and we cut back drastically"

This is a direct marketing point for Dyloject, per mgmt in the past. Their formulation of diflocenac has a much lower platelet response profile; one of the main reason that I invested originally (another being that Dyloject was easier to stock and cheaper).

Price action is encouraging today, at least we are moving away from that candy bar share price level. Sure would be nice to see us break a buck by the end of the week.

aj